Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ruxolitinib phosphate, momelotinib dihydrochloride monohydrate, nezulcitinib +22 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 11 Parkinson's papers of 6,009 | 0.67 |
| pathways Reactome | 31 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6149
Sealed predictions
- JAK1 in dopamine neurons, braak+0.10 (p 0.799) → -0.08 (p 0.838)receipt 6157
Swarm cases
receipt 6157: JAK1 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.741, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.741, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.13 (p 0.603, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.03, sign flips 3; without severely affected donors -0.08 (p 0.741, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for JAK1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts